Who owns HALOZYME THERAPEUTICS?

Tip: Access positions for across all investors

Analyze quarterly positions in Halozyme Therapeutics with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Halozyme Therapeutics stock

Who bought or sold HALOZYME THERAPEUTICS this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of Actions
M&G 37M $38M 1% Mar 2026
 View chart
Citadel Advisors 20M $20M -54% Mar 2026
 View chart
Steelhead Partners 19M $20B 100% Mar 2026
 View chart
Nuveen 12M $13M 0% Mar 2026
 View chart
Silverback Asset Management 11M $12M 13% Mar 2026
 View chart
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 11M $11M 0% Mar 2026
 View chart
Citigroup 10M $11M 100% Mar 2026
 View chart
Tpg Gp A 10M $10M 100% Mar 2026
 View chart
Angelo, Gordon & Co 10M $11M 100% Dec 2025
 View chart
Point72 Asset Management 7.5M $7.8M 0% Mar 2026
 View chart
Balyasny Asset Management 6.2M $6.5M 100% Mar 2026
 View chart
Calamos Advisors 5.7M $5.9M -1% Mar 2026
 View chart
MacKay Shields 5.4M $5.6M 3% Mar 2026
 View chart
Colony 3.8M $4.1M 100% Dec 2025
 View chart
Water Island Capital 3.0M $3.1M 0% Mar 2026
 View chart
Huntington Asset Advisors 3.0M $3.1M 22% Mar 2026
 View chart
Pier 88 Investment Partners 3.0M $3.1M 18% Mar 2026
 View chart
Advent Capital Management 2.8M $3.0M -34% Mar 2026
 View chart
Bnp Paribas Investment Partners 2.7M $2.9M 0% Dec 2025
 View chart
FMR 2.3M $2.5M -74% Dec 2025
 View chart
Aequim Alternative Investments 2.0M $2.2M 0% Dec 2025
 View chart
Man Group 1.9M $1.9M -5% Mar 2026
 View chart
Wells Fargo & Company 1.4M $1.5M 0% Mar 2026
 View chart
SSI Investment Management 1.3M $1.3M 0% Mar 2026
 View chart
Kohlberg Kravis Roberts & Co 915k $953k 0% Mar 2026
 View chart
Universal- Beteiligungs- und Servicegesellschaft mbH 750k $781k 0% Mar 2026
 View chart
Bank Of Montreal 634k $663k 100% Mar 2026
 View chart
Palisade Capital Management 550k $594k -79% Dec 2025
 View chart
Calamos Wealth Management 266k $277k 2% Mar 2026
 View chart
Oppenheimer Asset Management 170k $176k -3% Mar 2026
 View chart
Wiley Bros.-aintree Capital 131k $141k 0% Dec 2025
 View chart
Cutler Capital Management 110k $114k 0% Mar 2026
 View chart
UBS Group 64k $66k 100% Mar 2026
 View chart
Capital Investment Advisory Services 59k $61k 0% Mar 2026
 View chart
Mariner Wealth Advisors 59k $61k 0% Mar 2026
 View chart
Stephens 53k $55k 0% Mar 2026
 View chart
Barclays 53k $57k 100% Dec 2025
 View chart
Branch Banking & Trust Company 38k $39k 0% Mar 2026
 View chart
Raymond James Financial 34k $37k 100% Dec 2025
 View chart
Balboa Wealth Partners 28k $29k 0% Mar 2026
 View chart
Ameriprise Financial 22k $23k 0% Mar 2026
 View chart
Commonwealth Equity Services 20k $21k 0% Mar 2026
 View chart
Mml Investors Services 18k $19k 0% Mar 2026
 View chart
Morgan Stanley 15k $16k 100% Mar 2026
 View chart
MAI Wealth Advisors 15k $16k 0% Mar 2026
 View chart
Goldstein Advisors 14k $15k 0% Mar 2026
 View chart
Cetera Investment Advisers 12k $12k 0% Mar 2026
 View chart
Laffer Investments 2.0k $2.1M 0% Mar 2026
 View chart

Who sold out of Halozyme Therapeutics?

Fund or Company Name Date Sold Shares Held Valued At
Linden Advisors Sep 2025 68M $78M
UBS O'Connor Sep 2025 18M $21M
Jpmorgan Chase & Co Sep 2025 17M $20M
State Street Corporation Sep 2025 17M $19M
State of Wisconsin Investment Board Sep 2025 3.0M $3.4M
Leucadia National Corporation Dec 2025 2.3M $2.5M
Lazard Asset Management Dec 2025 1.4M $15k
Macquarie Group Sep 2025 1.2M $1.4M
Flossbach Von Storch Dec 2025 1.1M $1.1M
Ares Systematic Credit Dec 2025 200k $217k
Wealth Enhancement Advisory Services Dec 2025 21k $24k
Boussard & Gavaudan Investment Management Sep 2025 20k $22M
Insigneo Advisory Services Dec 2025 15k $16k
Brian McDonald Sep 2025 10k $11k
CoreCap Advisors Dec 2025 5.0k $5.4k